Millennium Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-18,645
Closed -$118K 7312
2022
Q4
$118K Buy
18,645
+6,546
+54% +$36.2K ﹤0.01% 5524
2022
Q3
$62K Buy
+12,099
New +$76K ﹤0.01% 6115
2022
Q2
Sell
-85,834
Closed -$305K 7762
2022
Q1
$305K Buy
85,834
+40,514
+89% +$150K ﹤0.01% 5524
2021
Q4
$228K Buy
45,320
+29,773
+192% +$180K ﹤0.01% 5797
2021
Q3
$114K Buy
+15,547
New +$107K ﹤0.01% 6380
2020
Q2
Sell
-3,047
Closed -$11K 4757
2020
Q1
$11K Sell
3,047
-10,470
-77% -$54.2K ﹤0.01% 3758
2019
Q4
$85K Sell
13,517
-11,502
-46% -$146K ﹤0.01% 4047
2019
Q3
$350K Sell
25,019
-28,278
-53% -$466K ﹤0.01% 3477
2019
Q2
$787K Buy
+53,297
New +$1.43M ﹤0.01% 2950
2018
Q2
Sell
-22,916
Closed -$1.41M 4306
2018
Q1
$1.41M Buy
22,916
+10,343
+82% +$546K ﹤0.01% 2523
2017
Q4
$676K Buy
+12,573
New +$748K ﹤0.01% 2945
2017
Q3
Sell
-12,499
Closed -$677K 3981
2017
Q2
$677K Sell
12,499
-3,755
-23% -$174K ﹤0.01% 2646
2017
Q1
$579K Buy
+16,254
New +$557K ﹤0.01% 2738

Millennium Management's FSTX Position: Q1 2023 in Review

Millennium Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 18,645 shares — an estimated $118K sold.

Millennium Management first reported a position in FSTX in Q1 2017 and held it in 13 quarters. The position peaked at $1.41M in Q1 2018. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

  • Millennium Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Millennium Management sold 18,645 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $118K.
  • Millennium Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2017 and held it in 13 quarters.
  • Millennium Management's F-star Therapeutics, Inc. Common Stock position peaked at $1.41M in Q1 2018.
  • 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.